Danaher Corporation

What they do

Danaher operates through three segments—Biotechnology, Life Sciences, and Diagnostics—offering equipment, consumables, software, and services. Its solutions support biotherapeutics research, development, and manufacturing, as well as diagnostics and life science research. The company uses a direct sales model and generates a high level of recurring revenue from a geographically diverse customer base.

Revenue drivers

• Biotechnology — Offers equipment, consumables, software, and services for the research, development, manufacture, and delivery of biological medicines, including monoclonal antibodies, vaccines, and cell and gene therapies.
• Life Sciences — Provides instruments, consumables, and services for life science research, delivering its strongest quarter in several years in Q2 2026.
• Diagnostics — Sells diagnostic products and services, including respiratory testing, which is separately tracked in core revenue metrics.

Recent performance

In Q2 2026, net earnings were $870 million, or $1.23 per diluted share, up 60% year-over-year. Revenues increased 5.5% to $6.3 billion, with non-GAAP core revenue up 3.0% and up 4.5% excluding respiratory testing. Operating cash flow was $1.5 billion and free cash flow was $1.3 billion. Bioprocessing orders grew mid-teens in the quarter, though customer project timing impacted revenue.

Strategy

Danaher focuses on three strategic priorities: strengthening competitive advantage through the Danaher Business System (DBS), enhancing its portfolio in attractive science and technology markets, and attracting exceptional talent. The company continues to pursue acquisitions and investments, including the completed acquisition of Masimo, which closed earlier than anticipated. Management emphasizes capital deployment optionality and long-term shareholder value creation, while continuously assessing its portfolio for potential divestitures.

Risks

• Global economic conditions — Elevated inflation, interest rates, and policy disruptions from the 2025 U.S. administration change can affect operational costs and demand.
• Intense competition — Danaher faces significant competition, which could lead to decreased demand, market share loss, or price reductions.
• Dependence on innovation — Growth depends on timely development, commercialization, and customer acceptance of new and enhanced products and services.
• Acquisition integration — The integration of acquired businesses, such as Masimo, involves risks that could affect expected benefits and financial results.

Outlook

For Q3 2026, management expects non-GAAP core revenue to increase 2.0% to 3.0% year-over-year. For full year 2026, core revenue is expected to increase 3.0% to 4.0%, and adjusted diluted EPS guidance was raised to $8.45–$8.60 from a prior range of $8.35–$8.55. Management expects to exit 2026 at a mid-single-digit core revenue growth rate, driven by end-market recovery and recent growth initiatives.